Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday July 23.
The Four Horsemen Are Trampling Over Big Pharma: Regeneron (NASDAQ:REGN), Gilead (NASDAQ:GILD), Biogen Idec (NASDAQ:BIIB), Celgene (NASDAQ:CELG), GlaxoSmithKline (NYSE:GSK)
The days of big pharma names like GlaxoSmithKline (GSK) may be giving way to smaller, stronger biotechs, such as Cramer's "Four Horsemen": Regeneron (REGN), Gilead (GILD), Biogen Idec (BIIB) and Celgene (CELG). Sales of these four surpass those of GSK, and while it was thought that the biotechs would be taken over by larger pharmaceutical names, these biotechs are now too big and too rich to be taken over. Cramer wouldn't second-guess small biotech.
Something Old, Something New: PepsiCo (NYSE:PEP), Puma Biotechnology (NYSE:PBYI). Other stocks mentioned: Plug Power (NASDAQ:PLUG), Restoration Hardware (NYSE:RH), Cummins (NYSE:CMI), Skechers (NYSE:SKX)
Cramer suggests owning individual stocks rather than ETFs and ETNs. He thinks it is possible to make money in growth stocks that are familiar and speculative stocks that might be new names. Pepsico (PEP) reported a great quarter and raised its guidance. Management is cutting costs and developing popular brands. Pepsico belongs to the consumer packaged group, which is one of the weakest sectors. Although 8% growth doesn't sound fantastic, compared with other food stocks, it is impressive.
Puma Biotechnology (PBYI) is a stock whose valuation seems stretched, although it might deserve that premium price. It rallied an astounding amount, 295%, because of very positive data on a breast cancer drug. Competing drugs failed to improve survival rates, but Puma's treatment showed success. Cramer thinks Puma could fetch a bid from a larger company.
Cramer took some calls:
Plug Power (PLUG) has done a series of secondaries, and each time, the stock goes down. Cramer thinks PLUG has more bark than bite and is not fond of it.
Cummins (CMI) has been a winner, but has been downgraded. This is not a stock to trade on earnings; it is a long-term good story with decent risk/reward.
CFO Interview: Jack Hartung, Chipotle Mexican Grill (NYSE:CMG)
Chipotle Mexican Grill (CMG) reported an astounding quarter. It beat earnings by 41 cents, and revenues grew 28%. Same store sales rose 17.3%, which was the best number in 8 years. CMG has raised prices moderately to deal with higher raw costs, and has improved efficiency in the stores. Management raised guidance, and the stock rallied. It has risen 21% since Cramer got behind it in January.
CFO Jack Hartung said that while the company wants to support U.S. ranchers, it is not easy to find quality grass-fed beef domestically, and CMG has had to purchase Australian beef. In cases where the beef is not naturally raised, CMG puts signs up to warn customers, who then may switch to chicken or vegetarian options. Jack Hartung said he isn't considering a stock split, even though shares have a high dollar amount.
CMG is concentrating on how to get customers through the stores in the most efficient manner, and customer satisfaction is increasing. In addition, customers have the option of ordering through mobile devices before coming to the store. CMG is experimenting with a global payment system.
CEO Interview: Moshe Gavrielov, Xilinx (NASDAQ:XLNX)
When a company delivers disappointing results, is it a time to buy or to stay away? Xilinx (XLNX) makes programmable logic devices and customized chips. Cramer owns XLNX for his charitable trust, and was disappointed by the quarter; he thinks management should have pre-announced a shortfall. The stock fell 14.3% at one point during the day. This is the second guide down in revenue for Xilinx, and Cramer asked, "Why should we believe the stock will bounce back?" CEO Moshe Gavrielov said the turnaround is a "question of when, not if."
A large issue was a delay out of China, and Gavrielov expects a "surge" by December of this year. However, Cramer pointed out confident remarks about China that were said by management earlier, and he said he bought the stock for his charitable trust based on the bullish remarks. Gavrielov reiterated that "multi-phase deployment in China" was an issue, and said delays were the main reason, although he expressed hope for stronger news in December. Cramer asked "Why didn't you pre-announce that you had a dramatic decline?" Gavrielov pointed out that XLNX did not miss guidance dramatically.
Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.